Tag: Trisenox

Historically infamous as a poison, a specific form of arsenic is used for treatment in modern medicine, particularly for a specific type of leukemia. Today, arsenic trioxide (brand name Trisenox) is a cornerstone of therapy for acute promyelocytic leukemia (APL) and has dramatically improved patient outcomes.

Arsenic trioxide, an inorganic compound with a long history in medicine, was approved by the FDA in 2000 under the brand name Trisenox® for the treatment of acute promyelocytic leukemia (APL). This once highly fatal blood cancer can now be managed with an ato injection, particularly when used in combination with other therapies.

Historically a notorious poison, arsenic has a unique regulatory status within pharmacology and is notably **not** classified as a controlled substance under the Drug Enforcement Administration's (DEA) schedule. A specific formulation, however, serves as a modern, prescription medication for certain cancers.

Arsenic trioxide (ATO), also known by its brand name Trisenox, has transformed the prognosis for patients with a specific and aggressive type of blood cancer. A key component in modern cancer protocols, ATO is primarily used to treat Acute Promyelocytic Leukemia (APL) by targeting and destroying the specific leukemia cells.